MannKind announces 30-week results from Phase 4 INHALE-3 study

MannKind Corporation announced top-level 30-week results from its Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during the extension phase. The completer analysis which included all people on inhaled insulin, evaluated two separate groups – one that utilized Afrezza over 30 weeks, and a second group of patients who switched to Afrezza at week 17 from usual care, defined as multiple daily injections, an automated insulin delivery system, or a pump without automation. There was continued improvement in the Afrezza-treated group, with additional subjects achieving A1c less than7% at 30 weeks – a 100% increase from baseline. Switching from usual care to Afrezza at week-17 allowed more than double the subjects to achieve A1c less than7% at week-30, compared to the number at goal at week-17. “The data from the extension phase of this study showed that more people living with T1D are able to reach target A1c levels when they remain on Afrezza or switch to Afrezza from usual care – whether they are using multiple daily injections or pumps,” said Michael Castagna, PharmD, CEO for MannKind Corporation. “We believe this data demonstrates to healthcare practitioners that Afrezza is an effective tool for their patients who want to improve their glycemic control.”